冠昊生物收盘上涨3.16%，滚动市盈率217.00倍，总市值38.13亿元

Company Overview - Guanhao Biological Technology Co., Ltd. specializes in the research, development, production, and sales of regenerative medical materials and regenerative medical implants [1] - The company is involved in the production of Class II and III implant materials and artificial organs, as well as medical hygiene materials and dressings [1] - Guanhao is participating in two "13th Five-Year" national key research and development projects focused on tissue repair and regenerative materials [1] Financial Performance - As of the latest Q3 2024 report, the company achieved a revenue of 278 million yuan, representing a year-on-year decrease of 9.97% [1] - The net profit for the same period was approximately 27.84 million yuan, down 32.55% year-on-year [1] - The sales gross margin stood at 78.64% [1] Market Position - The company's stock closed at 14.38 yuan, with a rise of 3.16%, resulting in a rolling price-to-earnings (PE) ratio of 217.00 [1] - Guanhao's total market capitalization is 3.813 billion yuan [1] - In comparison, the average PE ratio for the medical device industry is 46.46, with a median of 33.07, placing Guanhao at the 113th position in the industry [1][2] Institutional Holdings - As of Q3 2024, there are 20 institutions holding shares in Guanhao, all of which are funds, with a total holding of 1.1988 million shares valued at 14 million yuan [1]